134 related articles for article (PubMed ID: 37935198)
1. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.
He L; Yu C; Qin S; Zheng E; Liu X; Liu Y; Yu S; Liu Y; Dou X; Shang Z; Wang Y; Wang Y; Zhou X; Liu B; Zhong Y; Liu Z; Lu J; Sun L
Mol Cell; 2023 Nov; 83(22):4000-4016.e6. PubMed ID: 37935198
[TBL] [Abstract][Full Text] [Related]
2. PSMD14 Targeting Triggers Paraptosis in Breast Cancer Cells by Inducing Proteasome Inhibition and Ca
Lee HJ; Lee DM; Seo MJ; Kang HC; Kwon SK; Choi KS
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269789
[TBL] [Abstract][Full Text] [Related]
3. Identification of 4-arylidene curcumin analogues as novel proteasome inhibitors for potential anticancer agents targeting 19S regulatory particle associated deubiquitinase.
Yue X; Zuo Y; Ke H; Luo J; Lou L; Qin W; Wang Y; Liu Z; Chen D; Sun H; Zheng W; Zhu C; Wang R; Wen G; Du J; Zhou B; Bu X
Biochem Pharmacol; 2017 Aug; 137():29-50. PubMed ID: 28476333
[TBL] [Abstract][Full Text] [Related]
4. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinase PSMD14 promotes ovarian cancer progression by decreasing enzymatic activity of PKM2.
Sun T; Liu Z; Bi F; Yang Q
Mol Oncol; 2021 Dec; 15(12):3639-3658. PubMed ID: 34382324
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
7. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα.
Yang P; Yang X; Wang D; Yang H; Li Z; Zhang C; Zhang S; Zhu J; Li X; Su P; Zhuang T
Oncogene; 2024 Jan; 43(4):248-264. PubMed ID: 38017133
[TBL] [Abstract][Full Text] [Related]
8. Deubiquitinase PSMD14 enhances hepatocellular carcinoma growth and metastasis by stabilizing GRB2.
Lv J; Zhang S; Wu H; Lu J; Lu Y; Wang F; Zhao W; Zhan P; Lu J; Fang Q; Xie C; Yin Z
Cancer Lett; 2020 Jan; 469():22-34. PubMed ID: 31634528
[TBL] [Abstract][Full Text] [Related]
9. Novel insights into the non-canonical roles of PSMD14/POH1/Rpn11 in proteostasis and in the modulation of cancer progression.
Bustamante HA; Albornoz N; Morselli E; Soza A; Burgos PV
Cell Signal; 2023 Jan; 101():110490. PubMed ID: 36241058
[TBL] [Abstract][Full Text] [Related]
10. The Deubiquitinase Inhibitor b-AP15 and Its Effect on Phenotype and Function of Monocyte-Derived Dendritic Cells.
Schmidt M; Altdörfer V; Schnitte S; Fuchs AR; Kropp KN; Maurer S; Müller MR; Salih HR; Rittig SM; Grünebach F; Dörfel D
Neoplasia; 2019 Jul; 21(7):653-664. PubMed ID: 31132676
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinating enzyme PSMD14 facilitates tumor growth and chemoresistance through stabilizing the ALK2 receptor in the initiation of BMP6 signaling pathway.
Seo D; Jung SM; Park JS; Lee J; Ha J; Kim M; Park SH
EBioMedicine; 2019 Nov; 49():55-71. PubMed ID: 31685442
[TBL] [Abstract][Full Text] [Related]
12. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
Vdovin A; Jelinek T; Zihala D; Sevcikova T; Durech M; Sahinbegovic H; Snaurova R; Radhakrishnan D; Turi M; Chyra Z; Popkova T; Venglar O; Hrdinka M; Hajek R; Simicek M
Nat Commun; 2022 Nov; 13(1):6820. PubMed ID: 36357400
[TBL] [Abstract][Full Text] [Related]
13. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
15. Deubiquitinating enzyme PSMD14 promotes tumor metastasis through stabilizing SNAIL in human esophageal squamous cell carcinoma.
Zhu R; Liu Y; Zhou H; Li L; Li Y; Ding F; Cao X; Liu Z
Cancer Lett; 2018 Apr; 418():125-134. PubMed ID: 29331416
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.
Byrne A; McLaren RP; Mason P; Chai L; Dufault MR; Huang Y; Liang B; Gans JD; Zhang M; Carter K; Gladysheva TB; Teicher BA; Biemann HP; Booker M; Goldberg MA; Klinger KW; Lillie J; Madden SL; Jiang Y
Exp Cell Res; 2010 Jan; 316(2):258-71. PubMed ID: 19732767
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzyme PSMD14 facilitates gastric carcinogenesis through stabilizing PTBP1.
Li J; Li Y; Xu F; Sun B; Yang L; Wang H
Exp Cell Res; 2022 Jun; 415(2):113148. PubMed ID: 35405117
[TBL] [Abstract][Full Text] [Related]
18. Blockade of deubiquitinating enzyme PSMD14 overcomes chemoresistance in head and neck squamous cell carcinoma by antagonizing E2F1/Akt/SOX2-mediated stemness.
Jing C; Duan Y; Zhou M; Yue K; Zhuo S; Li X; Liu D; Ye B; Lai Q; Li L; Yao X; Wei H; Zhang W; Wu Y; Wang X
Theranostics; 2021; 11(6):2655-2669. PubMed ID: 33456565
[TBL] [Abstract][Full Text] [Related]
19. CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.
Thangavadivel S; Zelle-Rieser C; Olivier A; Postert B; Untergasser G; Kern J; Brunner A; Gunsilius E; Biedermann R; Hajek R; Pour L; Willenbacher W; Greil R; Jöhrer K
Oncotarget; 2016 Nov; 7(48):78605-78618. PubMed ID: 27732933
[TBL] [Abstract][Full Text] [Related]
20. A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.
Yerlikaya A; Okur E; Baykal AT; Acılan C; Boyacı I; Ulukaya E
J Proteomics; 2015 Jan; 113():315-25. PubMed ID: 25305590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
